Κυριακή 18 Φεβρουαρίου 2018

A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report

In general, dexamethasone is a required component drug in various combination chemotherapies for treating multiple myeloma, and its efficacy has been widely recognized. However, administration of dexamethasone...

http://ift.tt/2EAiCzQ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου